Table 4.
Evaluation of autoantibodies to ECH1 and HNRNPA2B1 in lung cancer diagnosis.
| AUC (95% CI) | p | Sensitivity (%) | Specificity (%) | YI | PPV (%) | NPV (%) | Accuracy (%) | Cutoff | |
|---|---|---|---|---|---|---|---|---|---|
| Anti-ECH1 | |||||||||
| LC vs NC | 0.799 (0.731–0.867) | <0.001 | 62.2 | 95.5 | 0.577 | 93.3 | 71.4 | 78.8 | 0.163 |
| COPD vs NC | 0.482 (0.396–0.567) | 0.672 | — | — | — | — | — | — | — |
| LC vs COPD | 0.801 (0.732–0.870) | <0.001 | 62.2 | 97.8 | 0.600 | 93.3 | 72.1 | 80.0 | 0.163 |
| LC vs NC+COPD | 0.800 (0.735–0.865) | <0.001 | 62.2 | 96.6 | 0.589 | 90.3 | 83.6 | 85.1 | 0.163 |
| Anti-HNRNPA2B1 | |||||||||
| LC vs NC | 0.874 (0.818–0.929) | <0.001 | 72.2 | 95.5 | 0.677 | 81.2 | 77.2 | 83.8 | 0.202 |
| COPD vs NC | 0.479 (0.394–0.564) | 0.627 | — | — | — | — | — | — | — |
| LC vs COPD | 0.886 (0.832–0.940) | <0.001 | 80.0 | 94.4 | 0.744 | 93.5 | 82.5 | 87.2 | 0.144 |
| LC vs NL+COPD | 0.880 (0.828–0.932) | <0.001 | 82.2 | 88.8 | 0.710 | 78.7 | 90.9 | 86.6 | 0.137 |
COPD: Chronic obstructive pulmonary disease; NC: normal control; LC: lung cancer; PPV: positive predictive value; NPV: negative predictive value; YI: Youden's Index